Lamotrigine and hemodialysis in bipolar disorder: Case analysis of dosing strategy with literature review

Bipolar Disorders

Volumn 12, Issue 4, 2010, Pages 446-449

  Kaufman, Kenneth R ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Anti epileptic drug; Bipolar disorder; End stage renal disease; Epilepsy; Extraction factor; Hemodialysis; Lamotrigine; Therapeutic drug monitoring

Indexed keywords

LAMOTRIGINE;

ADULT; ARTICLE; BIPOLAR DISORDER; CASE REPORT; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MONITORING; EPILEPSY; HEMODIALYSIS; HUMAN; HYPOMANIA; KIDNEY FAILURE; MALE; MENTAL DISEASE; PRIORITY JOURNAL;

ANTIMANIC AGENTS; BIPOLAR DISORDER; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TREATMENT OUTCOME; TRIAZINES;

EID: 77954841031     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2010.00818.x     Document Type: Article

References (29)

1. Kaufman KR. Anticonvulsants in sports: ethical considerations. Epilepsy Behav 2007, 10:268-271.
2. Geddes JR, Calabrese JR, Goodwin GH. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomized trials. Br J Psychiatry 2009, 194:4-9.
3. van der Loos ML, Mulder PG, Hartong EG. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009, 70:223-231.
4. Tilhonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 2009, 109:10-14.
5. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007, 27:263-272.
6. Krupitsky EM, Rudenko AA, Burakov AM. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res 2007, 31:604-611.
7. Bellino S, Paradiso E, Bogetto F. Pharmacotherapy of borderline personality disorder. CNS Drugs 2008, 22:671-692.
8. Eisenberg E, River Y, Shifrin A, Krivoy N. Antiepileptic drugs in the treatment of neuropathic pain. Drugs 2007, 67:1265-1289.
9. Poyurovsky M, Glick I, Koran L. Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. J Psychopharmacol 2008, 10.1177/0269881108099215, doi
10. Uzun O. Lamotrigine as an augmenting agent to treatment-resistant obsessive-compulsive disorder: a case report. J Psychopharmacol 2010, 24:425-427.
11. Labiner DM, Ettinger AB, Fakhoury TA. Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. Epilepsia 2009, 50:434-442.
12. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998, 7:163-165.
13. Ng B, Camacho A, Bardwell W, Sewell DD. Lamotrigine for agitation in older patients with dementia. Int Psychogeriatr 2009, 21:207-208.
14. Khinchi MS, Nielsen KA, Dahl M, Wolf P. Lamotrigine therapeutic thresholds. Seizure 2008, 17:391-395.
15. Hirsch LJ, Weintraub D, Du Y. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004, 63:1022-1026.
16. Lacerda G, Krummel T, Sabourdy C, Ryvlin P, Hirsch E. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006, 67(Suppl. 4):S28-S33.
17. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 2006, 45:1061-1075.
18. Brodtkorb E, Reimers A. Seizure control and pharmacokinetics of antiepileptic drugs in pregnant women with epilepsy. Seizure 2008, 17:160-165.
19. Ohman I, Beck O, Vitols S, Tomson T. Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia 2008, 49:1075-1080.
20. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal human. Clin Pharmacol Ther 1987, 42:535-541.
21. Wootton R, Soul-Lawton J, Rolan PE, Fook Sheung CTC, Cooper JDH, Posner J. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Br J Clin Pharmacol 1997, 43:23-27.
22. Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. Drugs Exp Clin Res 1993, 19:25-32.
23. Diagnostic and Statistical Manual of Mental Disorders 1994, Fourth Edition, Washington, DC, American Psychiatric Association
24. Varon J, Marik PE. The diagnosis and management of hypertensive crises. Chest 2000, 118:214-227.
25. Patsalos PN, Berry DJ, Bourgeois BF. Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008, 49:1239-1276.
26. Leo RJ, Narendran R. Anticonvulsant use in the treatment of bipolar disorder: a primer for primary care physicians. Prim Care Companion J Clin Psychiatry 1999, 1:74-84.
27. Goldberg JF. Optimizing treatment outcomes in bipolar disorder under ordinary conditions. J Clin Psychiatry 2008, 69(Suppl. 3):11-19.
28. Werz MA. Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release. Ther Clin Risk Manag 2008, 4:1035-1046.
29. Marcellin P, de Bony F, Garret C. Influence of cirrhosis on lamotrigine pharmacokinetics. Br J Clin Pharmacol 2001, 51:410-414.